+$0.06 (+2.7%)
Closing price May 26, 2022
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with chronic hepatitis B virus infection.